News | July 26, 2024
Piramal Pharma Q1 FY25 net loss narrows
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
This surgery presented unique challenges, particularly due to the size of the gallbladder and the multitude of stones
Rocuronium Bromide Injection had estimated annual sales of USD 54 million in the US (IQVIA MAT August 2023).
Animations, colors, and shapes help to improve poor situational awareness, which is responsible for 81.5% of anesthesia-related errors
Ephedrine Sulfate Injection USP, 50 mg/mL had annual sales of USD 52 mn in the United States
Rocuronium Bromide Injection is a neuromuscular blocking agent
Clinical studies are expected to start in Q2 2023.
Themis will market this drug with the brand name REMITHEM.
This is the first injectable product approval from our General Sterile Facility (F-3) which was inspected in August, 2022.
Subscribe To Our Newsletter & Stay Updated
